Novel HIF inhibitor roxadustat will offset biosimilar erosion to drive growth in the anemia in CKD market.
By Kevin Shannon, Analyst
16 April 2016
I am an analyst at Datamonitor Healthcare, currently located in San Diego, California, where I am a member of the cardio...
Read full bio
The anemia in CKD market is forecast to decline from 2015 to 2017 due to the launch of biosimilar epoetin alfa in the US, then will experience growth from 2017 to 2024 following the launch of roxadustat. Sales of Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in the US currently make up 43% of the total anemia in chronic kidney disease (CKD) market, and physicians expect to switch 49% of patients receiving branded epoetin alfa to biosimilars according to Datamonitor Healthcare’s survey of 356 nephrologists and hematologists. The widespread uptake of biosimilars in the US is expected to decrease the value of the anemia in CKD market after their launch in 2016. This decrease is forecast to be offset by the launch of novel HIF inhibitor roxadustat in 2018. Datamonitor Healthcare expects roxadustat to become the market leader by value in the anemia in CKD market with $2.0bn in sales in 2024. Roxadustat uptake will be driven by its superior convenience and safety compared to current ESAs, as well as its ability to reduce the use of intravenous (IV) iron as demonstrated in clinical trials.
Anemia in chronic kidney disease market sales in the US, Japan, and five major EU markets, by class, 2015–24
Get your free demo today – simply fill in the form to the right.